Bocidelpar

Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) [1][2].

Product Specifications

CAS Number

[2095128-20-2]

Product Name Alternative

ASP0367; MA-0211

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bocidelpar.html

Purity

98.08

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(O)C[C@H](C)CCCOC1=CC=CC=C1CN2C(C)=CN=C2C3=CC=C(C(F)(F)F)C=C3

Molecular Formula

C25H27F3N2O3

Molecular Weight

460.49

References & Citations

[1]Ito M, et al. Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study. Muscle Nerve. 2022 Jan;65 (1) :110-120.|[2]Diniz Gulden, et al. A Quick Glance at the Therapeutic Approaches for Neuromuscular Disorders. Clues for Differential Diagnosis of Neuromuscular Disorders. Cham: Springer International Publishing, 2023. 329-344.